Post by ProductLife Group
201,239 followers
๐๐ป ๐ถ๐ป๐ฐ๐ผ๐ฟ๐ฟ๐ฒ๐ฐ๐ ๐ข๐๐ ๐ฑ๐ผ๐ฒ๐๐ป'๐ ๐ท๐๐๐ ๐ฐ๐ผ๐๐ ๐บ๐ผ๐ป๐ฒ๐. ๐๐ ๐ฐ๐ผ๐๐๐ ๐ต๐ฒ๐ฎ๐น๐๐ต. Set it too high: workers inhale highly potent APIs. Occupational illness. OSHA violations. Legal liability. Set it too low: millions wasted on closed-system isolators and Category 5 containment suits - for compounds that the science says could be handled safely in a standard downflow booth. ๐๐ฃ ๐๐๐ผ๐๐ ๐ข๐๐ฃ๐ช๐๐๐๐ฉ๐ช๐ง๐๐ฃ๐, ๐ฉ๐๐๐ง๐ ๐๐จ ๐ฃ๐ค ๐ข๐๐ง๐๐๐ฃ ๐๐ค๐ง ๐๐ง๐ง๐ค๐ง ๐ค๐ฃ ๐๐๐ฉ๐๐๐ง ๐จ๐๐๐. And yet, under-qualified assessors consistently get it wrong - most often at the route-to-route extrapolation step, where oral animal data must be precisely converted to human inhalation risk. Our new white paper - ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ถ๐ป ๐ข๐ฐ๐ฐ๐๐ฝ๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ ๐ฝ๐ผ๐๐๐ฟ๐ฒ ๐๐ถ๐บ๐ถ๐๐ (๐ข๐๐) - gives you the scientific and regulatory rigour to get it right: ๐นOEL and OEB defined, with containment implications at each band ๐นFull formula walkthrough: NOAEL, uncertainty factors (UF1โUF5), bioavailability correction (ฮฑ), and MF for long half-life compounds ๐นThe route-to-route and dermal traps that most assessors miss ๐นOSHA/NIOSH, COSHH, ECHA/REACH, and ISPE Containment Manual alignment Authored by Vishnu Jatoth, M.S (Pharm.), ERT and AMIT SALVI, ProductLife Group's certified toxicologists for EHS managers, industrial hygienists, and anyone making containment investment decisions in potent compound manufacturing. ๐ ๐ฅ๐ฒ๐ฎ๐ฑ ๐ถ๐ ๐ต๐ฒ๐ฟ๐ฒ: https://lnkd.in/dnWX44r5 ๐ ๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ:ย https://lnkd.in/eA_wMcH5 #OccupationalSafety #HPAPI #OEL #IndustrialHygiene #PharmaceuticalManufacturing #EHS #COSHH #WorkerSafety #PLG